Clinical trial · Interventional
Autotaxin: a Potential Biomarker for Breast Cancer.
Is Autotaxin a Promising Biomarker for Breast Cancer
NCT05680311CI-TRIAL-00063451completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this clinical trial is to test the efficiency of Autotaxin (ATX) as a biomarker for breast cancer patients. The main questions it aims to answer are; * is ATX a reliable tumor marker for breast cancer patients in diagnosis * can ATX differentiate cancer patients from non-cancer ones
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| measurement of serum autotaxin serum level | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Breast Cancer Patients
- description
- Group of patients with verified breast cancer diagnosis
- interventionNames
- Biological: measurement of serum autotaxin serum level
- type
- SHAM_COMPARATOR
- label
- Non-Cancer patients
- description
- Group of healthy patients with no verified any type of cancer.
- interventionNames
- Biological: measurement of serum autotaxin serum level
Primary outcomes (1)
- measure
- Autotaxin as a tumor marker
- timeFrame
- preoperative period
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Preoperatively diagnosed breast cancer patients with no synchronous cancer and without known hepatic or other inflammatory disorders. Exclusion Criteria: * Patients with benign breast diseases and no known cancer history.
References
Publications (3)
- RESULTLukasiewicz S, Czeczelewski M, Forma A, Baj J, Sitarz R, Stanislawek A. Breast Cancer-Epidemiology, Risk Factors, Classification, Prognostic Markers, and Current Treatment Strategies-An Updated Review. Cancers (Basel). 2021 Aug 25;13(17):4287. doi: 10.3390/cancers13174287. PMID 34503097
- RESULTGaetano CG, Samadi N, Tomsig JL, Macdonald TL, Lynch KR, Brindley DN. Inhibition of autotaxin production or activity blocks lysophosphatidylcholine-induced migration of human breast cancer and melanoma cells. Mol Carcinog. 2009 Sep;48(9):801-9. doi: 10.1002/mc.20524. PMID 19204929
- RESULTBrindley DN, Tang X, Meng G, Benesch MGK. Role of Adipose Tissue-Derived Autotaxin, Lysophosphatidate Signaling, and Inflammation in the Progression and Treatment of Breast Cancer. Int J Mol Sci. 2020 Aug 18;21(16):5938. doi: 10.3390/ijms21165938. PMID 32824846